Device-Enabled Disease Management for Heart Failure

Service-based heart failure management initiatives are evidently unable to deliver economic benefits, as evidenced by the "South Texas CHF Disease Management Project", results of which were presented at the American Heart Association meeting in November, but device companies think they can. Several , including Medtronic and CHF Solutions are setting out to demonstrate the benefits of device-enabled fluid management in congestive heart failure patients. Fluid overload accounts for 90% of hospitalizations for heart failure, and heart failure is the number one reason for hospital admissions in the US.

As if the words "disease management" weren't already a business killer, the results of a study on disease management for congestive heart failure presented at the American Heart Association meeting in November tapped another nail into the concept. Disease management usually refers to a kind of service-based oversight designed to improve both the clinical outcomes and the economics of treating patients. Congestive heart failure (CHF) has long been the target of such initiatives. It is the number one cause for hospitalizations in the US, and the health care system spends $40 billion on the disease annually. Disease management in heart failure thus seeks to manage medical therapies and symptoms efficiently to avoid frequent or long hospitalizations.

The South Texas CHF Disease Management Project, results of which were presented at AHA and published in Circulation, studied 1,069 patients that had heart failure and ventricular dysfunction, who were...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By 

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By 

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By 

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.